Program
eptinezumab
Also written as “Eptinezumab”, “ALD403” and “ALD403 (Eptinezumab)”.
Its studies are mostly in Migraine Disorders · Cluster Headache, led by 2 companies.
Drug pageEptinezumab: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| H. Lundbeckits history only | 223 open or running | phase 4since Feb 23, 2022 | Apr 16, 2012 | Mar 26, 2027phase 3 · NCT04965675 |
| Dr George Medvedevits history only | 11 open or running | phase 3since May 16, 2024 | May 16, 2024 | Mar 2028phase 3 · NCT06428838 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 9 earlier studies, Apr 16, 2012 to Jun 3, 2020.
- Jun 9, 2016Named eptinezumabINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ALD403
- Aug 28, 2020Phase 1 study in Migraine DisordersH. Lundbeck · NCT04537429 · 28 enrolled · United States
- Dec 24, 2020Phase 3 study in Cluster HeadacheH. Lundbeck · NCT04688775 · 231 enrolled · United States, Belgium, Czechia and more
- Feb 23, 2021Phase 3 study in Migraine DisordersH. Lundbeck · NCT04772742 · 193 enrolled · China, Georgia, Korea, Republic of and more
- Jun 4, 2021Phase 3 study in Migraine DisordersH. Lundbeck · NCT04921384 · 981 enrolled · China, Georgia, Japan and more
- Jul 7, 2021Phase 3 study in Chronic Migraine in ChildrenH. Lundbeck · NCT04965675 · 285 planned · United States, Argentina, Canada and more
- Sep 7, 2021Phase 1 study in HealthyH. Lundbeck · NCT05045781 · 20 enrolled · China
- Sep 22, 20212 phase 3 studiesH. Lundbeck · NCT05064397, NCT05064371
- Dec 7, 2021Phase 3 study in Migraine DisordersH. Lundbeck · NCT05164172 · 600 planned · United States, Argentina, Canada and more
- Feb 23, 2022Phase 4 study in Migraine DisordersH. Lundbeck · NCT05284019 · 32 enrolled · United States
- Jul 6, 2022Phase 4 study in Migraine DisordersH. Lundbeck · NCT05452239 · 608 enrolled · United States, Australia, Denmark and more
- May 31, 2023Phase 3 study in Episodic MigraineH. Lundbeck · NCT05897320 · 315 planned · United States, Argentina, Canada and more
- May 16, 2024Dr George Medvedev’s first study: phase 3 study in Migraine DisordersNew to Dr George MedvedevDr George Medvedev · NCT06428838 · 102 planned · Canada
- Nov 20, 2024Phase 4 study in Migraine DisordersH. Lundbeck · NCT06701526 · 164 enrolled · United States
- Oct 16, 2026Primary completion moved from 2026-09-05 to 2027-03-26Date moved laterphase 3 · +7 months · NCT04965675
Ahead
- Mar 26, 2027Primary completion: phase 3 study in Chronic Migraine in ChildrenH. Lundbeck · NCT04965675
- Jul 6, 2027Primary completion: phase 3 study in Episodic MigraineH. Lundbeck · NCT05897320
- Mar 2028Primary completion: phase 3 study in Migraine DisordersDr George Medvedev · NCT06428838
- Apr 30, 2028Primary completion: phase 3 study in Migraine DisordersH. Lundbeck · NCT05164172
TargetBeta
“Calcitonin gene-related peptide inhibitor”ChEMBL 37, by rule
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06701526Migraine Disorders · United States | 4 | Completed | H. Lundbeck | Sep 2, 2026 | 164 |
| NCT06428838Migraine Disorders · Canada | 3 | By invitation | Dr George Medvedev | Mar 2028 | 102 |
| NCT05897320Episodic Migraine · United States, Argentina, Canada and more | 3 | Recruiting | H. Lundbeck | Jul 6, 2027 | 315 |
| NCT05452239Migraine Disorders · United States, Australia, Denmark and more | 4 | Completed | H. Lundbeck | Oct 22, 2024 | 608 |
| NCT05284019Migraine Disorders · United States | 4 | Terminated | H. Lundbeck | Feb 17, 2023 | 32 |
| NCT05164172Migraine Disorders · United States, Argentina, Canada and more | 3 | Recruiting | H. Lundbeck | Apr 30, 2028 | 600 |
| NCT05064397Cluster Headache · United States, Denmark, Finland and more | 3 | Completed | H. Lundbeck | Jun 29, 2023 | 131 |
| NCT05064371Migraine Disorders · Japan | 3 | Completed | H. Lundbeck | Jun 8, 2024 | 160 |
| NCT05045781Healthy · China | 1 | Completed | H. Lundbeck | Jul 20, 2021 | 20 |
| NCT04965675Chronic Migraine in Children · United States, Argentina, Canada and more | 3 | Recruiting | H. Lundbeck | Mar 26, 2027 | 285 |
| NCT04921384Migraine Disorders · China, Georgia, Japan and more | 3 | Completed | H. Lundbeck | Oct 1, 2024 | 981 |
| NCT04772742Migraine Disorders · China, Georgia, Korea, Republic of and more | 3 | Completed | H. Lundbeck | May 23, 2022 | 193 |
| NCT04688775Cluster Headache · United States, Belgium, Czechia and more | 3 | Completed | H. Lundbeck | Jun 14, 2023 | 231 |
| NCT04537429Migraine Disorders · United States | 1 | Completed | H. Lundbeck | Oct 20, 2022 | 28 |
| NCT04418765Migraine Disorders · United States, Belgium, Bulgaria and more | 3 | Completed | H. Lundbeck | Jul 15, 2021 | 892 |
| NCT04336449Healthy · Japan | 1 | Completed | H. Lundbeck | Aug 13, 2020 | 18 |
| NCT04152083Migraine Disorders · United States, Georgia | 3 | Completed | H. Lundbeck | Jul 8, 2020 | 485 |
| NCT02985398Migraine Disorders · United States | 3 | Completed | H. Lundbeck | Apr 2018 | 128 |
| NCT02974153Migraine Disorders · United States, Belgium, Czechia and more | 3 | Completed | H. Lundbeck | Nov 2017 | 1,121 |
| NCT02559895Migraine Disorders · United States, Georgia | 3 | Completed | H. Lundbeck | Feb 2017 | 898 |
| NCT02275117Migraine Disorders · United States, Australia, Georgia and more | 2 | Completed | H. Lundbeck | Mar 2016 | 665 |
| NCT01772524Migraine Disorders · United States | 1 | Completed | H. Lundbeck | Dec 2013 | 163 |
| NCT01579383Migraine Disorders · Australia | 1 | Completed | H. Lundbeck | Dec 2012 | 104 |
How it is read
Names in the registry
- “Eptinezumab”, 17 entries
- “ALD403”, 5 entries
- “ALD403 (Eptinezumab)”, 2 entries
Conditions, from the studies’ own filings
- Migraine Disorders, 19 studies
- Cluster Headache, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.